移植领域超百亿元BD大单！中国生物制药牵手赛诺菲

Group 1 - The core transaction involves China Biologic Products (01177.HK) entering into an exclusive licensing agreement with Sanofi for the development, production, and commercialization of the JAK/ROCK inhibitor, rovalpitin [1][4] - The agreement grants China Biologic Products a $135 million upfront payment and potential milestone payments of up to $1.395 billion, along with tiered royalties based on annual net sales of rovalpitin [4][5] - This transaction marks a record for the largest external licensing deal in the transplantation field for a Chinese pharmaceutical company, with a total estimated value exceeding 10.5 billion RMB [4][5] Group 2 - Rovalpitin, a first-in-class oral small molecule JAK/ROCK inhibitor, has been approved for use in patients with primary myelofibrosis and related conditions, indicating it is a mature product rather than an early-stage asset [4][5] - The deal is expected to enhance China Biologic Products' cash flow and support its R&D efforts while allowing for a global expansion under a light-asset model [5][6] - The transaction challenges the stereotype that Chinese innovative drugs can only export early-stage projects, providing a new paradigm for local pharmaceutical companies in global licensing and long-term revenue sharing [5][6] Group 3 - In recent years, China Biologic Products has been actively expanding its portfolio, including a $1.2 billion acquisition of siRNA innovator Hejia and a $951 million stake in Lixin Pharmaceuticals [6] - Despite these expansions, the company has faced challenges in reversing performance declines in some of its acquisitions, as seen with Haobor, which reported a revenue drop of 0.98% in 2025 [6] - For the first half of 2025, China Biologic Products reported revenues of approximately 17.57 billion RMB, a year-on-year increase of 10.71%, and a net profit of about 3.39 billion RMB, up 12.31% [6]